bioequivalence

Related by string. Bioequivalence . bio equivalence * * bioequivalence studies . research bioequivalence phases . pivotal bioequivalence *

Related by context. All words. (Click for frequent words.) 70 bioequivalency 65 bio equivalence 63 therapeutic equivalence 63 bioequivalence studies 63 bioequivalent 62 active comparator 61 pharmacokinetic studies 60 efficacy 60 noninferiority 60 non inferiority 59 pharmacokinetic 59 T Pred 58 clinical trials 58 GLP toxicology 58 #mg dosage [001] 58 thorough QT 58 DORIBAX 58 vitro dissolution 58 torezolid phosphate 58 anidulafungin 58 efficacy tolerability 58 pharmacodynamic properties 58 ICH guidelines 58 Dalbavancin 58 pharmacokinetic equivalence 57 retapamulin 57 Bioequivalence 57 faropenem 57 bicifadine 57 oral rivaroxaban 57 rilpivirine 57 GLP toxicology studies 57 balsalazide tablet 57 alvimopan 57 ONGLYZA ™ 57 Exforge HCT 57 CIP ISOTRETINOIN 57 Dacogen injection 57 atovaquone 57 tipranavir 57 casopitant 57 tolevamer 57 Tracleer R 56 placebo controlled studies 56 Exelbine 56 tobramycin 56 maximally tolerated dose 56 HCl capsules 56 Ereska 56 injectable formulations 56 rHuPH# 56 immunogenicity 56 Inhalation Solution 56 ORMD 56 zafirlukast 56 PIX# [002] 56 phase IIIb 56 riociguat 56 subcutaneously administered 56 tolerability 56 Anidulafungin 55 NeuroSTAT ® 55 adipiplon 55 JAK inhibitor 55 lopinavir ritonavir 55 stavudine d4T 55 Linjeta TM 55 Civacir 55 Amigal 55 bioavailability 55 clinical trial 55 metoprolol succinate 55 Phase Ib study 55 MoxDuo IR 55 cangrelor 55 RSD# 55 besylate 55 Doribax 55 peginesatide 55 liprotamase 55 Phase III trials 55 phase Ib 55 pharmacokinetic characteristics 55 favorable pharmacokinetic profile 55 Phase #/#a 55 CANCIDAS 55 viral kinetics 55 Lorqess 55 miconazole Lauriad ® 55 tablet formulation 55 Navelbine ® 55 Androxal TM 55 Dyloject TM 55 Focalin XR 55 rhLF 55 saquinavir 55 glatiramer acetate 55 lanthanum carbonate 55 ADVANCE PD 55 PrevOnco 55 protease inhibitor PI 55 tecarfarin 55 BRILINTA 55 lamivudine 55 ZEGERID Capsules 55 capsule formulation 55 MoxDuo TM IR 54 intranasal formulation 54 miconazole 54 pharmacodynamics PD 54 mesylate 54 acyclovir Lauriad R 54 SNRI 54 Exelbine NDA 54 paliperidone palmitate 54 carcinogenicity study 54 DASISION 54 lisdexamfetamine dimesylate 54 pegylated 54 tocilizumab 54 octreotide acetate 54 methylnaltrexone 54 MIRCERA 54 TYGACIL 54 silodosin 54 #mg #mg [002] 54 phase IIa 54 Phase 2b study 54 Drug Application 54 topical ocular 54 Kaletra tablets 54 Shire Laboratories 54 postapproval 54 phosphate binder 54 CIP TRAMADOL ER 54 radezolid 54 Octreolin 54 pharmacokinetic PK study 54 orBec 54 APF# 54 mg doses 54 Anthim 54 oral methylnaltrexone 54 Proellex TM 54 Advagraf 54 Valcyte 54 YONDELIS 54 NXL# 54 Cellegesic 54 placebo controlled trials 54 KAPIDEX 54 Phase Ib clinical 54 Phase IIa 54 Phase III clinical trials 54 AzaSite Plus 54 Enhanze Technology 54 Rasilez HCT 54 TLK# 54 Tekturna HCT 54 BLA filing 54 intravenous acetaminophen 54 clinical pharmacology studies 54 serotonin norepinephrine reuptake inhibitor 54 randomized controlled clinical trials 54 TELINTRA 54 Protelos 54 FACTIVE tablets 54 RSD# oral 53 Itopride 53 STEDESA 53 Elvitegravir 53 pharmacokinetics PK 53 Marketing Authorisation Application MAA 53 Ramelteon 53 Replagal 53 dosing 53 peg interferon 53 Tarceva TM 53 analgesic efficacy 53 Onrigin TM 53 dose proportionality 53 pharmacokinetics 53 desvenlafaxine 53 Fortovase 53 5mg #mg #mg 53 ribavirin RBV 53 Pegasys ® 53 Ceftobiprole 53 CELVAPAN H#N# 53 TMC# C# 53 Zenvia 53 investigational antiplatelet agent 53 blinded randomized placebo controlled 53 dronabinol 53 Phase 2a trial 53 levalbuterol 53 fenofibric acid 53 prucalopride 53 pharmacokinetic profiles 53 APTIVUS 53 palonosetron 53 pharmacodynamic profile 53 clinical endpoints 53 mcg dose 53 preclinical efficacy 53 tigecycline 53 postmarketing surveillance 53 Tasigna nilotinib 53 LibiGel ® 53 pharmacokinetic profile 53 hydrochloride capsules 53 Bifeprunox 53 dosing regimens 53 Hycamtin 53 Rhucin 53 Xinlay 53 balsalazide 53 IV acetaminophen 53 Bydureon 53 Mycamine 53 rasagiline 53 INTELENCE 53 UPLYSO 53 pharmacodynamics 53 ritonavir boosting 53 daptomycin 53 Targretin 53 COMFORT II 53 GAMMAGARD 53 Corlux 53 confirmatory clinical 53 NOXAFIL Oral Suspension 53 active moiety 53 docetaxel Taxotere ® 53 pharmacokinetic parameters 53 Ticagrelor 53 nonclinical studies 53 dalbavancin 53 Somatuline R Autogel R 53 PROMACTA 53 eliglustat tartrate 53 midodrine 53 REMINYL ® 53 intravenously administered 53 LIALDA 53 Nebido 53 micafungin 53 adenosine injection 53 AstraZeneca Toprol XL 53 FOLOTYN ® 53 tacrolimus ointment 53 Hyphanox 53 Onbrez Breezhaler 53 AZILECT ® 53 ipratropium bromide 53 FOSRENOL R 53 Candesartan 53 DAVANAT 53 Zensana 53 interferon gamma 1b 53 lamivudine zidovudine 53 RoACTEMRA 53 AZILECT R 53 TBC# 53 phase IIb clinical 53 XOPENEX 53 piperacillin tazobactam 53 febuxostat 53 tasimelteon 53 8mg 53 SILENOR TM 53 abacavir lamivudine 53 oritavancin 53 Kaletra lopinavir ritonavir 53 icatibant 53 oral prodrug 53 posaconazole 53 tramiprosate 53 Dasatinib 53 PREZISTA r 53 BAL# [002] 52 bovine thrombin 52 dosage regimen 52 gadobutrol 52 Ciclesonide 52 Carbidopa Levodopa 52 sevelamer carbonate 52 Riquent 52 nelfinavir 52 ADAGIO study 52 pharmacokinetic PK 52 NOXAFIL 52 orally disintegrating 52 1mg 2mg 52 JOULFERON 52 Calcium Acetate 52 EDEMA3 52 SYMBICORT 52 Phase #b/#a 52 exenatide 52 Navelbine 52 Phase IIa clinical 52 BLA submission 52 Azathioprine 52 mg uk 52 Solorel 52 BiDil XR 52 peginterferon alfa 2b 52 OMNARIS Nasal Spray 52 sorafenib tablets 52 comparator arm 52 Sular formulation 52 levetiracetam Keppra 52 tezampanel 52 macrolide antibiotic 52 preclinical studies 52 HCV RESPOND 2 52 Valtropin 52 Cloretazine 52 incyclinide 52 budesonide 52 ELADUR 52 PREOS 52 cGMP manufacture 52 interferon beta 1b 52 Cethromycin 52 fluticasone propionate 52 azficel T 52 CoFactor 52 Kaletra tablet 52 NanoCrystal technology 52 Marketing Authorization Applications 52 Q#IR 52 dose escalation trial 52 Starlix 52 Icatibant 52 ATPace TM 52 Anturol 52 fluvoxamine maleate 52 Focetria 52 EOquin 52 ENRICH trial 52 DPP4 52 Iloperidone 52 DURATION 52 Vfend 52 divalproex sodium 52 mg dose 52 budesonide inhalation suspension 52 ASCEND HF 52 KNS # 52 placebo controlled clinical trials 52 Zalbin 52 RezularTM 52 SOLODYN 52 balsalazide disodium 52 Phase IIB 52 ceftazidime 52 Carvedilol 52 achieved statistical significance 52 Mycophenolate Mofetil 52 administered subcutaneously 52 LY# [003] 52 Anzemet 52 USL# 52 candesartan cilexetil 52 pivotal bioequivalence 52 Aptivus 52 CELVAPAN 52 GSK# [002] 52 Relivar 52 Cobalt Pharmaceuticals 52 EmbraceAC 52 ALGRX 52 zidovudine AZT 52 oxycodone HCl 52 statistically significant superiority 52 FIRAZYR 52 bosutinib 52 glucosamine hydrochloride 52 delafloxacin 52 pharmacokinetics pharmacodynamics 52 rabeprazole 52 diabetic neuropathic pain 52 Rebif ® 52 Dynepo 52 Fodosine 52 GLP1 agonist 52 Rapaflo 52 JECFA 52 therefore therapeutically equivalent 52 levosimendan 52 interferon alfa 2b 52 pegloticase 52 AZILECT 52 sNDA 52 mg capsules 52 Proquin XR 52 Phase 1b clinical 52 Vernakalant 52 Plicera 52 Rhucin ® 52 ciclesonide 52 CGMP 52 refractory chronic lymphocytic 52 azelastine 52 mg canada 52 pharmacokinetic pharmacodynamic 52 PD LID 52 Fortical R 52 Cleviprex TM clevidipine 52 aliskiren 52 H#N# antigen 52 amprenavir 52 ZYFLO 52 ALTU 52 Phase III clinical 52 multicentre randomized 52 Reverset 52 pegylated interferon alfa 52 Non inferiority 52 amphotericin B 52 Telavancin 52 Focalin XR ® 52 fluvastatin 52 Dyloject 52 deferiprone 52 pharmacokinetic PK profile 52 darunavir 52 indacaterol 52 buccal tablet 52 AERx iDMS 52 topiramate Topamax 52 Entereg TM 52 MyVax 52 Panzem R NCD 52 Invirase 52 SEBIVO 52 pegylated interferons 52 Prosaptide 52 alogliptin 52 Sebivo 52 Sanvar R 52 LCP AtorFen 52 Inhalation Aerosol 52 dosing interval 52 Keppra XR 52 Spiriva HandiHaler 52 mirtazapine 52 fosbretabulin 52 Indiplon 52 Spiegelmer ® 52 INT# [002] 52 generic Copaxone 52 metformin hydrochloride 52 Omigard 52 KRN# 52 HuMax CD4 52 placebo controlled Phase III 51 Ropinirole 51 ruxolitinib 51 Pivotal Phase III 51 trabectedin 51 teduglutide 51 oral dosage 51 ritonavir boosted 51 virus HCV protease inhibitor 51 VIAject ® 51 abatacept 51 soft gelatin capsule 51 octagam ® 51 ganaxolone 51 desvenlafaxine succinate 51 Alinia 51 pharmacologically active isomer 51 LEP ETU 51 RHUCIN 51 GAMMAGARD LIQUID 51 Phase 1b trial 51 genotypic resistance 51 Joulferon 51 atazanavir 51 Lubiprostone 51 DU #b 51 HAART regimens 51 Torisel 51 investigational protease inhibitor 51 orally inhaled 51 Altabax 51 oxymorphone ER 51 guanfacine extended release 51 Eligen R B# 51 decitabine 51 maraviroc 51 BeneFIX 51 reslizumab 51 Oral NKTR 51 cephalosporin 51 Emezine R 51 #mg dose [001] 51 Firazyr 51 Phase IIb clinical 51 reboxetine 51 mg dosage 51 dosage regimens 51 successfully commercialize Iluvien 51 udenafil 51 oral diclofenac 51 Tredaptive 51 EGS# 51 rhThrombin 51 dose escalation clinical 51 ITAX 51 Arixtra 51 Sular ® 51 PDE4 inhibitor 51 topical diclofenac 51 Levetiracetam 51 SILENOR ™ 51 Telzir 51 ANDA filings 51 GSK# [001] 51 PSN# [002] 51 SPRIX ® 51 Perforomist ™ Inhalation Solution 51 Rebetol 51 Certriad 51 intravenous cyclophosphamide 51 Pruvel 51 Fludara 51 Promacta 51 Valortim ® 51 albinterferon alfa 2b 51 NDA resubmission 51 QNEXA 51 NasalFent 51 teriflunomide 51 Contrave 51 retrospective observational study 51 Copegus ribavirin 51 nucleoside analog 51 phase IIb 51 visilizumab 51 MERLIN TIMI 51 Engerix B 51 PrandiMet TM 51 ondansetron 51 Oracea TM 51 Novo Nordisk Victoza 51 FDA Approvable Letter 51 NEVO TM 51 tenofovir Viread 51 antiplatelet agent 51 multicenter randomized placebo controlled 51 Empatic 51 teriparatide 51 mealtime insulin 51 Dabigatran etexilate 51 THALOMID 51 Biologic License Application BLA 51 pegylated interferon 51 glatiramer 51 efavirenz EFV 51 fluconazole 51 dorzolamide 51 lansoprazole 51 SCH # 51 efficacy endpoints 51 eltrombopag 51 CCR5 antagonist 51 dose escalation study 51 CERVARIX R 51 acitretin 51 Diovan HCT 51 APTIMA HPV assay 51 HyQ 51 subcutaneous formulation 51 Specifid 51 CDP# 51 rosuvastatin calcium 51 guanfacine 51 Increlex R 51 LB# [003] 51 Pennsaid R 51 pioglitazone HCl 51 CaPre TM 51 double blinded placebo 51 LEVAQUIN ® 51 Darunavir 51 NVA# 51 TNF alpha inhibitor 51 postmarket surveillance 51 Phase IIa trial 51 Tolvaptan 51 NexACT ® 51 pyrazinamide 51 double blinded randomized 51 #.#mg 1mg 51 OFIRMEV 51 LPV r 51 Teriparatide 51 phosphate binders 51 randomized Phase III 51 Stavzor 51 carvedilol 51 intravenous dosing 51 Silenor ® doxepin 51 irbesartan 51 Centralized Procedure 51 MAA submission 51 rivastigmine 51 Soliris TM eculizumab 51 SinuNase TM 51 Zyflo CR 51 Liprotamase 51 INVEGA SUSTENNA 51 HepeX B 51 HCV SPRINT 51 CLIRS trial 51 amoxicillin clavulanate 51 oral ridaforolimus 51 zaleplon 51 phase IIa clinical 51 plus ribavirin 51 isatoribine 51 ARIKACE 51 ORENCIA ® 51 encapsulates siRNAs 51 telbivudine 51 AEGR 51 Retacrit 51 Cancidas 51 Ofloxacin 51 pomalidomide 51 tiotropium bromide 51 #D#C# 51 SILENOR 51 ASACOL 51 Zenvia Phase III 51 Prezista 51 clevudine 51 primary efficacy endpoints 51 Phase Ia 51 TRANSFORMS 51 SYMMETRY trial 51 Phase 2a clinical 51 Dual Opioid 51 NexACT 51 Diamyd r vaccine 51 Zenpep 51 Phase Ib 51 IL# PE#QQR 51 nonrandomized 51 Ambrisentan 51 fluoroquinolone antibiotic 51 generic Lovenox 51 tolerability profile 51 BYETTA ® 51 Femara letrozole 51 Heplisav 51 Loxapine 51 galantamine 51 controlled multicenter 51 Acetavance 51 surrogate endpoint 51 Announces Tentative Approval 51 sublingual tablets 51 filgrastim 51 TELCYTA 51 HFA MDI 51 systemic immunosuppressive drugs 51 galiximab 51 OncoVEX GM CSF 51 macrolide antibiotics 51 Poly ICLC 51 Phase IIb clinical trials 51 azacitidine 51 tinidazole 51 iniparib 51 Filgrastim 51 S/GSK# 51 Viramidine 51 Tekamlo 51 antiviral activity 51 dimebon 51 BCR ABL inhibitor 51 celgosivir 51 multiple ascending dose 51 PDUFA Date 51 Stedesa 51 thymalfasin 51 Relistor 50 vinorelbine tartrate 50 Soliris eculizumab 50 HGS# 50 Dapoxetine 50 pegylated interferon alfa 2a 50 fentanyl transdermal system 50 6R BH4 50 PEG PAL 50 Intermezzo ® NDA 50 pitavastatin 50 WHO prequalification 50 Iressa gefitinib 50 RELISTOR ® 50 Phase IIIb 50 enoxaparin sodium 50 CorVue ™ 50 pain palliation 50 recombinant interferon 50 Rhucin R 50 Xyrem ® 50 intravenous formulations 50 HZT 50 TMC# [001] 50 wilate ® 50 EXPAREL ™ 50 LT NS# 50 Japanese Encephalitis vaccine 50 dirucotide 50 vinorelbine 50 Mipomersen 50 Genz # 50 efalizumab 50 Targretin capsules 50 Numax 50 Losartan Potassium 50 diclofenac sodium 50 RE SURGE 50 docetaxel emulsion 50 dosing regimen 50 sitaxsentan 50 VIAject 50 sNDA submission 50 5mg #mg 50 ELND# 50 salmon calcitonin 50 treprostinil 50 TQT studies 50 Cefdinir 50 Nexavar sorafenib 50 fondaparinux 50 INKP 50 midstage clinical 50 Lamictal ODT 50 eszopiclone 50 zileuton CR 50 Androgel R 50 selegiline 50 equi analgesic doses 50 Cimzia ® certolizumab pegol 50 confirmatory Phase III 50 indiplon 50 Intuniv 50 PCV# 50 RECOTHROM R 50 Medicinal Products EMEA 50 pharmacokinetic interactions 50 Inhalation Powder 50 Lovaza TM 50 Pharmacokinetic 50 carcinogenicity studies 50 donepezil hydrochloride 50 RAPAFLO 50 peg IFN 50 FOSRENOL ® 50 orally administered 50 cGMPs 50 ginkgo extract 50 telaprevir 50 R#/MEM # 50 NV1FGF 50 xanthine oxidase inhibitor 50 CHAMPION PCI 50 nitazoxanide 50 TREDAPTIVE 50 midstage trials 50 amlodipine benazepril 50 preclinical toxicology 50 placebo controlled 50 Phase Ib II 50 Sunovion 50 Neurodex 50 preclinical 50 Welchol 50 Glycopyrrolate 50 Onrigin 50 dose regimens 50 Prestara TM 50 BrachySil 50 COREG CR 50 BioVant 50 CREON R 50 pharmacodynamic PD 50 Abacavir Sulfate 50 Prostate AdenoCarcinoma Treatment 50 Tygacil 50 echinocandin 50 omega interferon 50 Vilazodone 50 Triapine R 50 unfractionated heparin 50 Phase 2b clinical 50 noninferior 50 VFEND 50 Menerba 50 vicriviroc 50 peginterferon alpha 2a 50 ISENTRESS 50 preclinically 50 Paxil paroxetine 50 azilsartan medoxomil 50 LCP Tacro ™ 50 trastuzumab emtansine T DM1 50 Epoetin alfa 50 SYCREST 50 INC# 50 sildenafil citrate Viagra 50 ACTEMRA TM 50 Voraxaze 50 Gattex 50 rALLy trial 50 Arranon 50 Alogliptin 50 MoxDuo ® IR 50 oral transmucosal 50 randomized multicenter 50 dose escalation 50 Phase IIIb clinical 50 mertansine 50 losartan potassium 50 cathepsin K inhibitor 50 #mg dose [003] 50 lacosamide 50 mcg doses 50 gabapentin enacarbil 50 insulin glargine rDNA origin 50 Peg IFN 50 Cimzia R 50 multicenter Phase III 50 PS# [001] 50 Noxafil 50 Crofelemer 50 caspofungin 50 ISENTRESS raltegravir 50 Phase Ib clinical trials 50 Trizytek 50 lumiliximab 50 AVE# 50 racemic 50 fexofenadine 50 atrasentan 50 miconazole MBT 50 FDA Investigational Device 50 antidiabetic 50 lucinactant 50 EFAPROXYN 50 midstage studies 50 Pharmacokinetic studies 50 monotherapy 50 metformin HCl 50 Ribavirin 50 AIR CF2 50 5 HT3 antagonist 50 ZOLINZA 50 linear pharmacokinetics 50 randomized clinical trials 50 GTC recombinant human 50 sodium phenylbutyrate 50 QD dosing 50 ALVESCO R 50 antiviral efficacy 50 Ventavis ® 50 bromfenac 50 ganciclovir 50 PEGylated 50 ULTRASE 50 PrevOnco ™ 50 VPRIV 50 Phase IIb 50 Symbicort SMART 50 ULORIC 50 postmarketing studies 50 hGH CTP 50 deferoxamine 50 latrepirdine 50 VA# [002] 50 FavId 50 Interferon alpha 50 KADIAN ® 50 pramlintide metreleptin combination 50 Pemetrexed 50 Bicifadine 50 dabigatran etexilate 50 Clevudine 50 ambrisentan 50 JANUVIA 50 HPV vaccine Cervarix 50 eCTD format 50 Afresa 50 topical formulations 50 Enjuvia 50 Phase IIa proof 50 CLL8 50 MK #B 50 CIMZIA TM 50 dosage formulations 50 Augment Injectable 50 integrase inhibitor 50 methylnaltrexone bromide 50 blood clot dissolver 50 Renvela 50 MEVACOR 50 Rasagiline 50 Hatch Waxman exclusivity 50 mg Tablets 50 Kahalalide F 50 Preclinical studies 50 Lotrel ® 50 Trexima 50 Excellarate 50 Betaferon ® 50 brivaracetam 50 Betaseron ® 50 mesalazine 50 IRESSA 50 linagliptin 50 subcutaneous infusion 50 blinded placebo controlled 50 safflower produced 50 naproxcinod 50 Sporanox 50 Junovan 50 nalbuphine ER 50 viral kinetic 50 propafenone 50 Raptiva ® 50 Increlex ® 50 esomeprazole magnesium 50 CYT# QbG# 50 PREZISTA 50 INCB# [001] 50 NGX# 50 Metformin HCl 50 ZOMIG 50 oral iron chelator 50 Ondansetron Injection USP 50 Emend 50 Clonicel 50 Phase IIA 50 vemurafenib 50 Esomeprazole 50 Isolagen Process 50 FDA approvable letter 50 Belerofon 50 Sanofi Lovenox 50 Pixuvri 50 mapatumumab 50 lurasidone 50 calcineurin inhibitors 50 Dexilant 50 Marketing Authorization Application 50 sunitinib 50 ANDAs 50 alicaforsen enema 50 LEXIVA r 50 BRIM3 50 NUVIGIL ® 50 RhuDex ® 50 ziprasidone 50 Oxytrex 50 SEROQUEL R 50 Marketing Authorisation Application 50 therapeutic regimens 50 antiepileptics 50 SGS# 50 administered orally 50 Dose escalation 50 raltegravir 50 IFN Beta 50 Sestamibi 50 MONOVISC 50 ancrod 50 Humira adalimumab 50 Phase #b/#a trial 50 FM VP4 50 urocortin 2 50 ATryn ® 50 LC#m# 50 Biologics License Application 50 Horizant 50 oxybutynin chloride 50 Focalin XR R 50 etravirine 50 prGCD 50 pancreatic enzyme 50 budesonide MMX 50 USFDA 50 randomized multicenter trial

Back to home page